[Expansion of the genotypic and phenotypic spectrum and treatment of four children with Steroid-resistant nephrotic syndrome due to variants of TRPC6 gene].

Zhonghua Yi Xue Yi Chuan Xue Za Zhi

Department of Nephrology and Rheumatology, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou Key Laboratory of Children's Kidney Disease Research, Zhengzhou, Henan 450018, China.

Published: April 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To summarize the clinical and genetic characteristics, treatment and prognosis of four children with Steroid-resistant nephrotic syndrome (SRNS) due to variants of TRPC6 gene.

Methods: Clinical data of four children with SRNS admitted to Children's Hospital Affiliated to Zhengzhou University between May 2020 and August 2022 were collected. Peripheral blood samples were collected from the children and their parents, and whole exome sequencing was carried out. Sanger sequencing was used to verify the pathogenicity of the candidate variants among the children and their parents.

Results: All of the four children were found to harbor heterozygous variants of the TRPC6 gene, including c.523C>T (p.R175W), c.1327T>A (p.F443I), c.430G>C (p.E144Q) (unreported previously), and c.523C>T (p.R175W), which were all missense variants. Two of the children have shown a simple type, whilst two have shown a nephritis type, none had extrarenal phenotype. Comprehensive renal pathology of three children revealed focal segmental glomerulosclerosis (FSGS). Two children were treated with steroids combined with calcineurin inhibitors (CNIs), among whom one showed significant improvement in symptoms.

Conclusion: Discoveries of the novel c.430G>C variant and the new SRNS phenotype of the c.1327T>A variant have expanded the mutational and phenotypic spectrum of the TRPC6 gene, which has provided a reference for clinical diagnosis and genetic counseling for the families.

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.cn511374-20230309-00120DOI Listing

Publication Analysis

Top Keywords

variants trpc6
12
children
9
phenotypic spectrum
8
children steroid-resistant
8
steroid-resistant nephrotic
8
nephrotic syndrome
8
variants children
8
trpc6 gene
8
c523c>t pr175w
8
variants
5

Similar Publications

Transient receptor potential canonical 6 (TRPC6) is a receptor-operated nonspecific cation channel. To date, more than 30 TRPC6 variants have been reported to focal segmental glomerulosclerosis (FSGS), which can present from infancy to adulthood and is characterized by proteinuria and often nephrotic syndrome leading to kidney failure. These variants may exhibit gain-of-function (e.

View Article and Find Full Text PDF

Background And Hypothesis: Podocytopathy associated with likely pathogenic/pathogenic variants of TRPC6 (TRPC6-AP) has been recognised for about 20 years. As a result of its rarity however, the spectrum of clinical phenotypes and genotype-phenotype correlation of TRPC6-AP remains poorly understood. Here, we characterised clinical, histological, and genetic correlates of familial and sporadic patients with TRPC6-AP.

View Article and Find Full Text PDF

Podocytes express large-conductance Ca-activated K channels (BK channels) and at least two different pore-forming KCa1.1 subunit C-terminal splice variants, known as VEDEC and EMVYR, along with auxiliary β and γ subunits. Podocyte KCa1.

View Article and Find Full Text PDF
Article Synopsis
  • - Glomerulopathy leads to damage in the filtration barrier of the kidneys, often resulting in nephrotic syndrome (NS), which currently has limited treatment options primarily involving steroids with mixed effectiveness.
  • - A 7-year-old boy with a history of NS underwent genetic testing and biopsy, revealing abnormal changes, and after an initial steroid response, he was treated with anakinra and adalimumab, achieving remission without treatment for the past year.
  • - The case highlights the interplay of genetic and environmental factors in glomerular diseases and suggests that early intervention with biologic treatments may promote kidney recovery and reduce the need for steroids, indicating a need for further research.
View Article and Find Full Text PDF

Key Points: We conducted a clinical, genetic, and pathological analysis on 64 cases from 39 families with TRPC6-associated podocytopathy (TRPC6-AP). Analysis of 37,542 individuals excluded a major contribution of loss-of-function variants to TRPC6-AP, legitimating current drug discovery approaches. This study identifies key features of disease that can help intervention studies design and suggests similarities between TRPC6-AP and primary FSGS.

View Article and Find Full Text PDF